{
  "docId": "019de075-2875-74d4-8194-84b6aaf5cb83",
  "docSlug": "17078b9c485724b1d98591e3cd98aa3e",
  "documentTitle": "Kymera | Investor Presentation Deck | 60 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 60,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "The slide uses a split-screen comparison between healthy volunteer data and patient data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-2875-74d4-8194-84b6aaf5cb83/12",
  "deckHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83",
  "deckJsonHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83.json",
  "deckAnchorHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.22,
        "w": 0.44,
        "x": 0.04,
        "y": 0.32
      },
      "kind": "list",
      "text": "9 SAD cohorts; 8 subjects per cohort; 72 adult healthy subjects dosed; 5 MAD cohorts; 12 subjects per cohort; 60 adult healthy subjects dosed",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35a47032-34e3-4313-98dc-1854c06bcd43",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.44,
        "x": 0.52,
        "y": 0.62
      },
      "kind": "list",
      "text": "Safety, PK and PD comparable; Robust degradation of IRAK4; Promising clinical activity; Results support advancing to Phase 2",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75170653-936b-492f-b9bd-4e2b575c516b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.44,
        "x": 0.52,
        "y": 0.32
      },
      "kind": "list",
      "text": "1 cohort; 21 HS and AD patients; 75 mg (fed state); 28x daily doses",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dbfbdd44-61fe-4a87-a3ea-1833ad2bc721",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.44,
        "x": 0.04,
        "y": 0.062
      },
      "kind": "list",
      "text": "IRAK4 reduction to near lower limit; 85% inhibition of cytokines; >50% degradation in skin; well tolerated up to 200 mg with no SAEs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9e4e5f6-649d-4633-9950-3db466c2b3c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.58,
        "x": 0.21,
        "y": 0.04
      },
      "kind": "title",
      "text": "KT-474 Phase 1 Trial Design and Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f3ad243-40fb-483a-b378-9aa58b38f103",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}